The RADIANCE CED Study

Last updated: January 7, 2026
Sponsor: ReCor Medical, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Vascular Diseases

Circulation Disorders

Stress

Treatment

Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)

Clinical Study ID

NCT07231757
RADIANCE CED
  • Ages > 65
  • All Genders

Study Summary

The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible patients to support generalizability of outcomes to the broader Medicare population. Individual hospital enrollment is not required for this study and IRB exemption has been received by sponsor.

Eligibility Criteria

Inclusion

Common Inclusion Criteria:

  • Adults aged ≥65 years with uncontrolled hypertension

  • Stable regimen of blood pressure-lowering medication

Exclusion

Common Exclusion Criteria:

  • Hypertension due to secondary causes

  • Prior renal denervation treatment

  • Pregnancy

  • End-stage renal disease, dialysis, or kidney transplant

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)
Phase:
Study Start date:
November 21, 2025
Estimated Completion Date:
December 31, 2031

Connect with a study center

  • Henry Ford St. John Hospital

    Detroit 4990729, Michigan 5001836 48236
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.